Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantheus Holdings, Inc. (NASDAQ: LNTH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about Lantheus’ radiopharmaceutical-focused business, financial performance, risk factors, leadership changes and material transactions.
In its Form 8-K filings, Lantheus has reported key corporate events such as quarterly and year-to-date financial results, authorization of a stock repurchase program, acquisitions of Evergreen Theragnostics and Life Molecular Imaging, and the divestiture of its SPECT business. Filings also document leadership transitions, including the planned retirement of the Chief Executive Officer, the appointment of an Executive Chairperson and interim CEO, and changes in other senior roles. These disclosures help investors understand governance and compensation arrangements, including consulting and retirement agreements.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system and summarized on this page) typically contain segment information, discussion of products such as PYLARIFY, DEFINITY and Neuraceq, and descriptions of the company’s precision diagnostics, radiopharmaceutical oncology and strategic partnership activities. They also include extensive risk factor sections that discuss competitive dynamics, manufacturing and supply risks, regulatory considerations for PET imaging agents, and integration risks associated with acquisitions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as changes in outlook, major transactions, or updates on radiopharmaceutical pipeline assets like LNTH-2501 and MK-6240. Users can quickly see high-level insights from lengthy 10-K and 10-Q reports, as well as interpret 8-K items related to leadership changes or capital allocation. The filings page also surfaces insider and executive-related information reported in Forms 3, 4 and 5, allowing investors to monitor equity awards, vesting terms and other compensation-related details disclosed for Lantheus executives and directors.
Morgan Stanley filed an amended Schedule 13G showing updated ownership in Lantheus Holdings, Inc. common stock as of December 31, 2025. Morgan Stanley reports beneficial ownership of 1,640,837 shares, representing 2.5% of the class, with all voting and dispositive power shared among its reporting units.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 936,899 shares, or 1.4% of the class, with shared voting and dispositive power. Both reporting persons state they have ceased to be beneficial owners of more than five percent of Lantheus’s common stock and certify that the holdings are in the ordinary course of business and not for influencing control.
Farallon-affiliated funds and managers report a significant passive stake in Lantheus Holdings, Inc. As of the event date of 12/31/2025, the Farallon reporting group discloses beneficial ownership of 5,427,479 shares of Lantheus common stock, representing 8.2% of the outstanding Shares.
The Amendment notes internal leadership changes at Farallon entities. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased to be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen became a member and manager of several Farallon general partners and may be deemed a beneficial owner. The group certifies the holdings are not for changing or influencing control of Lantheus.
A shareholder has filed a notice of proposed sale of 6,713 shares of common stock, with an aggregate market value of
The shares to be sold were acquired through restricted stock vesting and employee stock purchase plan transactions between
Lantheus Holdings’ Chief Commercial Officer reported small changes in personal ownership of the company’s common stock related to transactions on December 15, 2024 and December 15, 2025. The transactions, each coded "F," involved the disposition of 356 shares at $93.48 and 368 shares at $66.57.
After the December 2024 transaction, the officer beneficially owned 25,055 shares. After the December 2025 transaction, beneficial ownership increased to 39,094 shares, which includes 143 shares acquired under the LNTH employee stock purchase plan on March 13, 2025, and 95 shares acquired under the same plan on September 12, 2025.
Lantheus Holdings, Inc. (LNTH)November 17, 2025, the reporting person received 14,285 restricted stock units that will vest in full on November 17, 2026. The filing shows direct ownership of 332,935 shares of common stock after this grant, plus additional indirect holdings through several trusts.
The insider also received a stock option covering 26,325 shares of Lantheus common stock with an exercise price of $52.50 per share. This option vests in full on November 17, 2026 and expires on November 17, 2035. Following this transaction, the reporting person beneficially owns 26,325 stock options in addition to the reported common stock positions.
Lantheus Holdings (LNTH) announced CEO transition arrangements. Effective November 6, 2025, the company entered into a Consulting Agreement with CEO Brian Markison and a Retirement and Separation Agreement. Mr. Markison will retire on December 31, 2025 and then serve as an advisor from January 1, 2026 through March 31, 2026, with an option to extend.
Under the Retirement Agreement, the company will continue his base salary through the Retirement Date. Within 60 days of December 31, 2025, he will receive a lump sum equal to his earned annual cash bonus for 2025, if any, based on actual company performance as determined in the ordinary course. Under the Consulting Agreement, he will receive an advisory fee of $83,333 per month. His outstanding equity awards will continue to vest through December 31, 2025 and thereafter follow the retirement features described in the company’s March 21, 2025 proxy statement.
Lantheus Holdings (LNTH) reported Q3 2025 results. Revenue was $384.0 million and diluted EPS was $0.41 as operating income declined to $43.6 million, reflecting higher sales, G&A, and R&D expenses and a higher effective tax rate of 34.5%.
Revenue mix shifted: PYLARIFY was $240.6 million (down year over year), DEFINITY rose to $81.8 million, and Neuraceq contributed $20.4 million following the Life Molecular acquisition. Year-to-date operating cash flow reached $300.0 million, while investing cash outflows reflected acquisitions of Evergreen ($268.9 million) and Life Molecular ($309.0 million). The company repurchased about $201.2 million of common stock year to date.
Cash and cash equivalents were $382.0 million versus $912.8 million at year-end, with intangibles and goodwill increasing from recent deals. LNTH classified its SPECT business as held for sale, with $76.6 million of assets and $28.6 million of liabilities. The $575.0 million 2.625% convertible notes remain outstanding; the $750.0 million revolving credit facility had no borrowings.
Lantheus Holdings (LNTH) announced a leadership transition and furnished Q3 results via press release. The company reported that CEO and director Brian Markison will retire effective December 31, 2025, and will resign from the board on that date. He will serve as a strategic advisor through at least March 31, 2026.
Mary Anne Heino was appointed Executive Chair effective November 7, 2025, and will become Interim Chief Executive Officer on January 1, 2026. She has served on the board since 2015 and previously led the company as CEO from 2015 to March 1, 2024. The filing notes no disagreements underlying Mr. Markison’s decision. President Paul Blanchfield is departing effective November 7, 2025, and Amanda Morgan will continue as Chief Commercial Officer, reporting to Ms. Heino.
Compensation details for Ms. Heino: base salary of $83,333 per month (annual rate $1,000,000); eligibility for a fiscal 2026 bonus with a 110% target, prorated; and equity awards with an aggregate grant date fair value of $1,500,000 on November 13, 2025, split 50% Black‑Scholes value for options and 50% RSUs, vesting in full on the first anniversary of the grant date.
Lantheus Holdings insider report: Robert J. Marshall Jr., listed as CFO and Treasurer and an officer of Lantheus Holdings (LNTH), reported a transaction dated 08/29/2025 on Form 4. The filing shows 727 shares of common stock were disposed (transaction code F) at a price of $54.9 per share, leaving 88,133 shares beneficially owned following the transaction. The ownership is reported as direct. The form is signed by an attorney-in-fact on 09/03/2025.
Insiders from Farallon-affiliated funds reported large open-market dispositions of Lantheus Holdings (LNTH) stock on August 19-20, 2025. The filing shows a sale of 41,000 shares on 08/19/2025 at $55.34 and a weighted-average sale of 3,365,000 shares on 08/20/2025 at $56.15. The reported beneficial ownership for the group fell from 6,842,227 shares after the first sale to 3,477,227 shares after the second sale. Footnotes identify the sellers as Farallon Funds and multiple managing members who disclaim beneficial ownership except for any pecuniary interest. The Form 4s were signed by an attorney-in-fact on 08/21/2025.
FAQ
What is the current stock price of Lantheus Holding (LNTH)?
What is the market cap of Lantheus Holding (LNTH)?
